Investments
185Portfolio Exits
63Funds
9Partners & Customers
1About Bay City Capital
Bay City Capital is a life sciences investment firm with a global diversified strategy ranging from seed stage to public companies, and including innovation, restructuring opportunities, and growth investing. Its investment team brings a wealth of experience across all areas of the life sciences industry. Nearly all of our partners have been with the firm for 12 years or more, and they are supported by over 20 investment professionals, distinguished advisers, and scientific advisory board members.
Bay City Capital Headquarter Location
750 Battery Street Suite 400
San Francisco, California, 94111,
United States
415-676-3830
Latest Bay City Capital News
May 5, 2021
Oculis S.A. , a Lausanne, Switzerland-based late-stage biopharmaceutical company focused on developing ophthalmic treatments to improve the sight and lives of patients, closed a US$57m Series C financing. The round was co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining the company’s existing investors, Bay City Capital, Brunnur Ventures, EarlyBird, funds managed by Tekla Capital Management, Pivotal bioVenture Partners, Nan Fung Life Sciences, Novartis Venture Fund, Silfurberg, as well as other existing investors. Led by Riad Sherif, MD, CEO, Oculis is a biopharmaceutical company focused on developing transformative innovative ophthalmic treatments to improve the sight and lives of patients. Proceeds from this financing will advance the company’s late-stage topical Ophthalmic portfolio, including: – Moving OCS-01 into Phase 3 trials in Diabetic Macular Edema (DME) and complete registration studies in the treatment of Inflammation and Pain following Ocular Surgery. – Advancing OCS-02 into Phase 2b trials targeting Dry Eye Disease (DED) and Chronic Anterior Uveitis as a steroid-sparing treatment. OCS-02 is a novel topical anti-TNF alpha antibody fragment, which has demonstrated efficacy and safety in two clinical proof of concept studies in moderate-to-severe DED and Acute Anterior Uveitis. In conjunction with the closing, Vanessa Huang, General Partner at BVCF Management, and Dr. Sylvia He, Managing Partner at Hyfinity Investments are joining the Oculis Board of Directors while Dr. David Weber and Dr. Thorsteinn Loftsson are stepping down. FinSMEs 06/05/2021
Bay City Capital Investments
185 Investments
Bay City Capital has made 185 investments. Their latest investment was in Oculis as part of their Series C on May 5, 2021.
Bay City Capital Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/5/2021 | Series C | Oculis | $57M | No | 12 | |
3/2/2020 | Series B | Xilio Therapeutics | $100.5M | Yes | 7 | |
3/18/2019 | Series B | Imara | $63M | No | 5 | |
1/4/2019 | Unattributed VC | |||||
1/4/2019 | Series B - II |
Date | 5/5/2021 | 3/2/2020 | 3/18/2019 | 1/4/2019 | 1/4/2019 |
---|---|---|---|---|---|
Round | Series C | Series B | Series B | Unattributed VC | Series B - II |
Company | Oculis | Xilio Therapeutics | Imara | ||
Amount | $57M | $100.5M | $63M | ||
New? | No | Yes | No | ||
Co-Investors | |||||
Sources | 12 | 7 | 5 |
Bay City Capital Portfolio Exits
63 Portfolio Exits
Bay City Capital has 63 portfolio exits. Their latest portfolio exit was Xilio Therapeutics on October 22, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
10/22/2021 | IPO | Public | 10 | ||
3/12/2020 | IPO | Public | 1 | ||
1/7/2020 | Merger | 2 | |||
Date | 10/22/2021 | 3/12/2020 | 1/7/2020 | ||
---|---|---|---|---|---|
Exit | IPO | IPO | Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 10 | 1 | 2 |
Bay City Capital Fund History
9 Fund Histories
Bay City Capital has 9 funds, including Bay City Bridge LLC.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
2/13/2018 | Bay City Bridge LLC | Multi-Stage Venture Capital | Closed | $2M | 1 |
10/25/2007 | Bay City Capital Fund V LP | ||||
11/22/2005 | Bay City Capital Fund IV LP | ||||
12/31/2000 | Bay City Capital Fund III LP | ||||
12/31/1999 | North American Nutrition and Agribusiness Fund |
Closing Date | 2/13/2018 | 10/25/2007 | 11/22/2005 | 12/31/2000 | 12/31/1999 |
---|---|---|---|---|---|
Fund | Bay City Bridge LLC | Bay City Capital Fund V LP | Bay City Capital Fund IV LP | Bay City Capital Fund III LP | North American Nutrition and Agribusiness Fund |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $2M | ||||
Sources | 1 |
Bay City Capital Partners & Customers
1 Partners and customers
Bay City Capital has 1 strategic partners and customers. Bay City Capital recently partnered with Takeda Pharmaceutical on November 11, 2016.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/9/2016 | Partner | Japan | Bay City Capital Partners with TDI, Takeda and Deerfield Management to Launch Bridge Medicines Launched in partnership with Takeda and healthcare investment firms Bay City Capital LLC and Deerfield Management , Bridge Medicines is a groundbreaking initiative that completes a seamless , fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases . | 1 |
Date | 11/9/2016 |
---|---|
Type | Partner |
Business Partner | |
Country | Japan |
News Snippet | Bay City Capital Partners with TDI, Takeda and Deerfield Management to Launch Bridge Medicines Launched in partnership with Takeda and healthcare investment firms Bay City Capital LLC and Deerfield Management , Bridge Medicines is a groundbreaking initiative that completes a seamless , fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases . |
Sources | 1 |
Bay City Capital Team
19 Team Members
Bay City Capital has 19 team members, including current Founder, Managing Director, Fred Craves.
Name | Work History | Title | Status |
---|---|---|---|
Fred Craves | Founder, Managing Director | Current | |
Susan Vuong | Chief Financial Officer | Current | |
David Beier | Managing Director | Current | |
Lionel Carnot | Managing Director | Current | |
Lionel Carnot | Managing Director | Current |
Name | Fred Craves | Susan Vuong | David Beier | Lionel Carnot | Lionel Carnot |
---|---|---|---|---|---|
Work History | |||||
Title | Founder, Managing Director | Chief Financial Officer | Managing Director | Managing Director | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.